DE20010297U1 - Enzyme-mediated modification of fibrin for tissue manipulation: fibrin formulations with peptides - Google Patents
Enzyme-mediated modification of fibrin for tissue manipulation: fibrin formulations with peptidesInfo
- Publication number
- DE20010297U1 DE20010297U1 DE20010297U DE20010297U DE20010297U1 DE 20010297 U1 DE20010297 U1 DE 20010297U1 DE 20010297 U DE20010297 U DE 20010297U DE 20010297 U DE20010297 U DE 20010297U DE 20010297 U1 DE20010297 U1 DE 20010297U1
- Authority
- DE
- Germany
- Prior art keywords
- fibrin
- peptide
- domain
- gel
- heparin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/04—Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Description
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically
Der Beschreibungstext wurde nicht elektronisch erfaßtThe description text was not recorded electronically
Claims (28)
- a) eine erste C-terminale Domäne, aufweisend eine Heparin bindende Peptidsequenz von Antithrombin III, und
- b) eine zweite N-terminale Domäne, aufweisend ein a2- Plasmininhibitor-Substrat für Faktor XIIIa.
- a) a first C-terminal domain, comprising a heparin-binding peptide sequence of antithrombin III, and
- b) a second N-terminal domain, comprising an a2 plasmin inhibitor substrate for factor XIIIa.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE20010297U DE20010297U1 (en) | 2000-06-08 | 2000-06-08 | Enzyme-mediated modification of fibrin for tissue manipulation: fibrin formulations with peptides |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE20010297U DE20010297U1 (en) | 2000-06-08 | 2000-06-08 | Enzyme-mediated modification of fibrin for tissue manipulation: fibrin formulations with peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
DE20010297U1 true DE20010297U1 (en) | 2000-08-31 |
Family
ID=7942648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE20010297U Expired - Lifetime DE20010297U1 (en) | 2000-06-08 | 2000-06-08 | Enzyme-mediated modification of fibrin for tissue manipulation: fibrin formulations with peptides |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE20010297U1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001083522A2 (en) * | 2000-05-01 | 2001-11-08 | Eidgenossisch Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
US6894022B1 (en) | 1998-08-27 | 2005-05-17 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
US7247609B2 (en) | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
US7601685B2 (en) | 1998-08-27 | 2009-10-13 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
US7659255B2 (en) | 2001-10-26 | 2010-02-09 | Paivi Liesi | Methods of inhibiting glutamate receptors by administering the tripeptide KDI |
US8226942B2 (en) | 2007-12-28 | 2012-07-24 | Kuros Biosurgery Ag | PDGF fusion proteins incorporated into fibrin foams |
US8318674B2 (en) | 2005-01-06 | 2012-11-27 | Kuros Biosurgery Ag | Local treatment of bone defects |
US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
US10589001B2 (en) | 2011-03-16 | 2020-03-17 | Kuros Biosurgery Ag | Pharmaceutical formulation for use in spinal fusion |
-
2000
- 2000-06-08 DE DE20010297U patent/DE20010297U1/en not_active Expired - Lifetime
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6894022B1 (en) | 1998-08-27 | 2005-05-17 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
US7601685B2 (en) | 1998-08-27 | 2009-10-13 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
WO2001083522A2 (en) * | 2000-05-01 | 2001-11-08 | Eidgenossisch Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
WO2001083522A3 (en) * | 2000-05-01 | 2002-03-28 | Eth Zuerich | Growth factor modified protein matrices for tissue engineering |
US7659255B2 (en) | 2001-10-26 | 2010-02-09 | Paivi Liesi | Methods of inhibiting glutamate receptors by administering the tripeptide KDI |
US7741436B2 (en) | 2001-10-26 | 2010-06-22 | Liesi Paeivi | Biologically active peptides and their use for repairing injured nerves |
US7247609B2 (en) | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
US8034618B2 (en) | 2001-12-18 | 2011-10-11 | Eldgenossische Technische Hochschule Zurich | PTH containing cell growth matrix |
US8318674B2 (en) | 2005-01-06 | 2012-11-27 | Kuros Biosurgery Ag | Local treatment of bone defects |
US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
US8226942B2 (en) | 2007-12-28 | 2012-07-24 | Kuros Biosurgery Ag | PDGF fusion proteins incorporated into fibrin foams |
US10589001B2 (en) | 2011-03-16 | 2020-03-17 | Kuros Biosurgery Ag | Pharmaceutical formulation for use in spinal fusion |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Skorstengaard et al. | Complete primary structure of bovine plasma fibronectin | |
Henkel et al. | Covalent Crosslinking between Molecules of Type I and Type III Collagen: The Involvement of the N‐Terminal, Nonhelical Regions of the αl (I) and al (III) Chains in the Formation of Intermolecular Crosslinks | |
Dimuzio et al. | Phosphophoryns—major noncollagenous proteins of rat incisor dentin | |
DE20010297U1 (en) | Enzyme-mediated modification of fibrin for tissue manipulation: fibrin formulations with peptides | |
EP0835934A3 (en) | Muteins of streptavidin | |
DE09004306T1 (en) | Copolymer 1-related polypeptides for use as molecular weight markers and for therapeutic use | |
EP2039769A3 (en) | Antimicrobial peptides and methods of use | |
KR960703942A (en) | Compounds having the antigenicity of hCG | |
ATE352617T1 (en) | SOLUBLE POLYPEPTIDE FRACTIONS OF LAG-3 PROTEIN; METHOD OF PRODUCTION; THERAPEUTIC COMPOSITION; ANTIDIOTYPICAL ANTIBODIES | |
DE69739918D1 (en) | PREPARATION OF GLYCERINE BY RECOMBINANT ORGANISMS | |
IL127806A0 (en) | Composition for altering hair growth and hair pigmentation | |
BR9706706A (en) | Dna plant cells barstar plant and dna use | |
Takagi et al. | Identification of dentin phosphophoryn localization by histochemical stainings | |
BG104267A (en) | Aminoterminally incised rantes as haemokin antagonists | |
US6096864A (en) | Peptides for use in wound treatment | |
AU3850997A (en) | Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines | |
Erdjument et al. | Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys | |
Ovadia | Isolation and characterization of a hemorrhagic factor from the venom of the snake Atractaspis engaddensis (Atractaspididae) | |
DE69722618D1 (en) | Peptide | |
AU5508396A (en) | Pcna binding substance | |
Kettlun et al. | Purification and characterization of two isoapyrases from Solanum tuberosum var. Ultimus | |
Sorensen et al. | Determination of the disulphide bridge arrangement of bovine histidine-rich glycoprotein | |
Dixit et al. | The isolation of crosslinked peptides of collagen involving α1-CB6 | |
IE902276L (en) | Serpin variants | |
CA2314605A1 (en) | Hm2 cdna related polypeptides and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R207 | Utility model specification |
Effective date: 20001005 |
|
R150 | Term of protection extended to 6 years |
Effective date: 20031006 |
|
R151 | Term of protection extended to 8 years |
Effective date: 20060922 |
|
R152 | Term of protection extended to 10 years |
Effective date: 20080915 |
|
R071 | Expiry of right |